Agios Pharmaceuticals, Inc. (AGIO) Reaches New 52-Week High at $72.33

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reached a new 52-week high on Thursday . The stock traded as high as $72.33 and last traded at $72.33, with a volume of 398,449 shares changing hands. The stock had previously closed at $70.43.

Several equities research analysts have weighed in on AGIO shares. BidaskClub downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada started coverage on shares of Agios Pharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price target for the company. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $83.00 price target (up from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 price target on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $75.20.

The firm’s market capitalization is $3.50 billion. The stock’s 50-day moving average price is $65.17 and its 200 day moving average price is $56.50.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The firm’s revenue was up 62.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.47) earnings per share. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post ($7.08) EPS for the current fiscal year.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 80,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $70.14, for a total transaction of $5,611,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott Biller sold 23,146 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $59.60, for a total transaction of $1,379,501.60. Following the sale, the insider now owns 8,410 shares of the company’s stock, valued at $501,236. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 228,408 shares of company stock valued at $14,976,478. 10.55% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the business. Swiss National Bank increased its stake in Agios Pharmaceuticals by 3.4% during the 1st quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock valued at $3,233,000 after purchasing an additional 1,800 shares in the last quarter. Spark Investment Management LLC increased its stake in Agios Pharmaceuticals by 139.9% during the 2nd quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock valued at $4,357,000 after purchasing an additional 49,400 shares in the last quarter. Geode Capital Management LLC increased its stake in Agios Pharmaceuticals by 8.3% during the 1st quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock valued at $15,410,000 after purchasing an additional 20,336 shares in the last quarter. Hood River Capital Management LLC increased its stake in Agios Pharmaceuticals by 2.3% during the 2nd quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock valued at $6,115,000 after purchasing an additional 2,626 shares in the last quarter. Finally, TD Asset Management Inc. increased its stake in Agios Pharmaceuticals by 4.9% during the 2nd quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $1,544,000 after purchasing an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/2955933/agios-pharmaceuticals-inc-agio-reaches-new-52-week-high-at-72-33.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.